Clinical Trials Logo

Clinical Trial Details — Status: Withdrawn

Administrative data

NCT number NCT00723918
Other study ID # U01NS32228_NARC011
Secondary ID NARC 011
Status Withdrawn
Phase Phase 2
First received July 28, 2008
Last updated February 8, 2018
Start date April 2009
Est. completion date January 2010

Study information

Verified date February 2018
Source Washington University School of Medicine
Contact n/a
Is FDA regulated No
Health authority
Study type Interventional

Clinical Trial Summary

The purpose of this study is to evaluate the effectiveness of methadone alone and in combination with SAB378 for the treatment of painful HIV-associated neuropathy.


Description:

Distal sensory polyneuropathy is the most common neurological complication of HIV disease and its treatment. To date no standard effective therapy has been identified.

In this study, scientists will evaluate the effectiveness of treating HIV-associated neuropathy with methadone alone and in combination with a novel cannabinoid SAB378. A cannabinoid is a molecule found only in the Cannabis plant. Cannabis and some cannabinoids are effective analgesics or pain relievers. The rationale for combination therapy is twofold: (1) medications with unique mechanisms of action may affect different aspects of neuropathic pain and (2) combination therapy may act synergistically—meaning the combined effect may be greater than the effect of each drug alone.

Approximately 84 participants will be enrolled in this double-blind, placebo-controlled, crossover study. Participants will be randomly assigned to three treatment groups—those receiving methadone and SAB378 placebo (an inactive substance), those receiving methadone and active SAB378, or those receiving methadone placebo and SAB378 placebo. All participants will be exposed to each of the 3 treatment groups during the study.

This trial is part of the Neurologic AIDS Research Consortium, an effective collaborative clinical study group dedicated to the study of HIV-associated neurological disease.


Recruitment information / eligibility

Status Withdrawn
Enrollment 0
Est. completion date January 2010
Est. primary completion date January 2010
Accepts healthy volunteers No
Gender All
Age group 18 Years and older
Eligibility Inclusion Criteria:

- HIV-1 infection

- HIV-associated neuropathy diagnosed by a neurologist

- Presence of at least a moderate pain score on the basis of completion of a baseline pain diary

- Stable antiretroviral regimen for at least 8 weeks prior to study entry.

- Hemoglobin = 8.0 g/dL for males and = 7.5 g/dL for females

Exclusion Criteria:

- Active AIDS-defining opportunistic infection within 45 days prior to study entry

- Renal insufficiency

- Chronic liver disease

- B12 deficiency

- Family history of hereditary neuropathy

- Discontinuation of dideoxynucleoside NRTI within 16 weeks prior to entry

- On neuroregenerative therapy

- Treatment with neurotoxic drugs within 120 days prior to entry

- Respiratory compromise

- Hypotension

- Active substance abuse or dependence

- History of alcohol-related complications within 6 months prior to screening

- Women of childbearing potential

Study Design


Related Conditions & MeSH terms


Intervention

Drug:
SAB378
SAB 15 mg per day for 5 days, the 15 mg BID (twice a day) for 5 days, then 15 mg TID (three times a day) to end of 28-day treatment period, in combination with active methadone 5 mg BID for 5 days, then 5 mg TID for 5 days, to maximum of 10 mg TID until end of 28-day treatment period
methadone
Methadone 5 mg BID (twice a day) for 5 days, then 5 mg TID (three times a day) for 5 days, to maximum of 10 mg TID, in combination with SAB placebo or SAB active drug titrated as above, to end of 28-day treatment period.
SAB placebo
an inactive substance
Methadone placebo
Methadone placebo

Locations

Country Name City State
United States University of New York Downstate Medical Center Brooklyn New York
United States University of Rochester Rochester New York
United States University of California, San Diego San Diego California

Sponsors (2)

Lead Sponsor Collaborator
Washington University School of Medicine National Institute of Neurological Disorders and Stroke (NINDS)

Country where clinical trial is conducted

United States, 

Outcome

Type Measure Description Time frame Safety issue
Primary Efficacy of methadone alone versus methadone and SAB378 for treatment of HIV-associated neuropathy At the end of each 4-week treatment period
Secondary Effect on quality of life, emotional functioning, cognitive functioning, safety At the end of each 4-week treatment period
See also
  Status Clinical Trial Phase
Completed NCT05560555 - Retrospective Study Collecting Neurological Follow-up of Hereditary Transthyretin Amyloidosis (ATTRv) Patients Included in B3461028 and B3461045.
Recruiting NCT02033057 - Muscular Electrostimulation of the Sedated and Mechanically Ventilated Critically Ill Patient. Analysis of the Effect on Acquired Muscular Weakness and Its Clinical Consequences. Phase 4
Withdrawn NCT02566941 - Neuromuscular Electrical Stimulation in the Critically Ill N/A
Completed NCT02442986 - Neurological Outcome in Surgical and Non-surgical Septic Patients N/A
Completed NCT02706314 - Impact of Human Blood Serum From Critically Ill Patients on Human Colon Neuronal Networks.
Completed NCT01076478 - Asian Study on Cilostazol Effectivity in Neuropathies of Diabetes Mellitus Type 2-A Pilot Study in the Philippines Phase 4
Completed NCT03373370 - Early Diagnosis of TTR Amyloidosis by Use of Molecular Biology
Completed NCT02846844 - Patients With Chemotherapy-induced Polyneuropathy Are Treated With an Integrated Program Including Massage, Mobilization in Posture and Transport Layers, Physical Exercises or With Whole-body Vibration Platform Training N/A
Recruiting NCT05950867 - Prevalence of Wild-type TTR Cardiac Amyloidosis in Patients With Polyneuropathy of Unknown Cause. N/A
Terminated NCT00832572 - Study of Ranexa in Patients With Coronary Artery Disease and Painful Polyneuropathy Phase 4
Completed NCT00614562 - Neurally Adjusted Ventilatory Assist (NAVA) in Patients With Critical Illness Associated Polyneuropathy / or Polymyopathy (CIP/M) Phase 1
Completed NCT01302275 - Oxcarbazepine for the Treatment of Chronic Peripheral Neuropathic Pain Phase 4
Terminated NCT01088256 - Efficacy of Etoricoxib on Peripheral Hyperalgesia Phase 2
Not yet recruiting NCT01047488 - Imipramine and Pregabalin Combination in Painful Polyneuropathy Phase 4
Recruiting NCT06414746 - Hereditary Transthyretin Amyloidosis Polyneuropathy in Patients With Carpal Tunnel Syndrome in Russia
Completed NCT04201418 - A Multicenter Observational Study to Evaluate the Effectiveness of Patisiran in Patients With Polyneuropathy of ATTRv Amyloidosis With a V122I or T60A Mutation
Completed NCT01450163 - Evaluate The Efficacy and Safety Of Pregabalin In Prevention, Reduction of Oxaliplatin-Induced Painful Neuropathy Phase 3
Recruiting NCT05040373 - Patisiran-Lipid Nanoparticle (LNP) Pregnancy Surveillance Program
Not yet recruiting NCT02666456 - The Influence of Sensory Phenotype on the Risk of Developing Neuropathic Pain N/A
Completed NCT00259974 - RIMAG Study: Trial of Rituximab Versus Placebo in Polyneuropathy Associated With Anti-MAG IgM Monoclonal Gammopathy Phase 3